PART I . Overview We are a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through our PROteolysis TArgeting Chimera, or PROTAC, protein degradation platform, we are pioneering the development of a new class of therapeutics designed to harness the bodys ow n natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. We have designed and optimized our propr...
Q2 FY2026 — expected 2026-09-09
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-24 | 2025-12-31 | 0001628280-26-011226 | EDGAR | 119K words |
| 2025-02-11 | 2024-12-31 | 0001655759-25-000016 | EDGAR | — |
| 2024-02-27 | 2023-12-31 | 0001655759-24-000018 | EDGAR | — |
| 2023-02-23 | 2022-12-31 | 0001655759-23-000010 | EDGAR | — |
| 2022-02-28 | 2021-12-31 | 0001628280-22-004262 | EDGAR | — |
| 2021-03-01 | 2020-12-31 | 0001564590-21-009857 | EDGAR | — |
| 2020-03-16 | 2019-12-31 | 0001564590-20-011004 | EDGAR | — |
| 2019-03-26 | 2018-12-31 | 0001564590-19-009357 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-05 | 2025-09-30 | 0001628280-25-049527 | EDGAR | 33K words |
| 2025-08-06 | 2025-06-30 | 0001655759-25-000139 | EDGAR | — |
| 2025-05-01 | 2025-03-31 | 0001655759-25-000085 | EDGAR | — |
| 2024-10-30 | 2024-09-30 | 0001655759-24-000131 | EDGAR | — |
| 2024-07-30 | 2024-06-30 | 0001655759-24-000118 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0001655759-24-000060 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0001655759-23-000093 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0001655759-23-000079 | EDGAR | — |
| 2023-05-05 | 2023-03-31 | 0001655759-23-000041 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001655759-22-000054 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001655759-22-000027 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0001655759-22-000016 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-18 | 0001628280-26-019026 | EDGAR | 1K words |
| 2026-02-24 | 0001628280-26-010865 | EDGAR | — |
| 2026-02-12 | 0001628280-26-007463 | EDGAR | — |
| 2025-12-08 | 0001628280-25-055682 | EDGAR | — |
| 2025-11-05 | 0001628280-25-049235 | EDGAR | — |
| 2025-10-24 | 0001628280-25-046259 | EDGAR | — |
| 2025-10-20 | 0001628280-25-045445 | EDGAR | — |
| 2025-10-06 | 0001628280-25-044212 | EDGAR | — |
| 2025-09-17 | 0001655759-25-000147 | EDGAR | — |
| 2025-08-08 | 0001655759-25-000141 | EDGAR | — |
153 total filings indexed. 123 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001655759 |
| Ticker | ARVN |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.arvinas.com |
| Listed | 2018-09-27 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report